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1.1 Obesity: diagnosis and treatment 
In recent decades, obesity and its metabolic complications have become one of the 
biggest public health issues worldwide. According to the data of World Health 
Organization (WHO), the prevalence of obesity has nearly tripled between 1975 and 
2016. In 2016, more than 1.9 billion adults were overweight, of whom over 650 million 
were obese (WHO 2018). Furthermore, obesity is a serious problem not just for adults 
but children also. The prevalence of obesity in children has dramatically increased in the 
last few years (Sahoo, Sahoo et al. 2015). In 2016, 41 million children under the age of 
5 were overweight or obese in 2016 and over 340 million children and adolescents aged 
5-19 were overweight or obese. Furthermore, obesity increases the risk of developing 
several comorbidities such as Type 2 diabetes mellitus (T2DM), high blood pressure, 
high blood cholesterol and high triglyceride levels, thereby reduces life quality and 
expectancy. Overweight and obesity are most common in developed and developing 
countries (Hruby and Hu 2015, Hales, Carroll et al. 2017). The cost of medical 
treatment of obesity and of the obesity-related diseases put a large economic burden on 
the individual and nations also (Levy, Levy et al. 1995, Birmingham, Muller et al. 1999, 
Tremmel, Gerdtham et al. 2017). Besides increased health care expenditure, obesity also 
imposes further costs in the form reduced ability to work, increased morbidity and 
mortality. 
1.1.1 Obesity and its metabolic complications 
Obesity is most commonly caused by a combination of excessive food intake, lack 
of physical activity, and genetic susceptibility (Yazdi, Clee et al. 2015). Occasionally it 
can be triggered by medications (Bernstein 1987, Ness-Abramof and Apovian 2005), 
endocrine disorders (Pujanek, Bronisz et al. 2013) or mental disorder (Bleich, Cutler et 
al. 2008). Obesity is a condition in which excess fat has accumulated in the body, such 




classified by body mass index (BMI, calculated by a person's weight in kilograms 
divided by the square of his height in meters), and further evaluated in terms of fat 
distribution via the waist circumference and body fat percentage. A person with a BMI 
of 18.5-24.9 kg/m² has a normal weight. A BMI of 25 to <30 kg/m² is defined as 
overweight and BMI ≥ 30 kg/m² is classified as obese, BMI ≥40 kg/m² defined as 
extreme obese (NIH 1998) (Table 1). 
 
Table 1 Classification of overweight and obesity by BMI, waist circumference and associated 
disease risk. 
Table was adopted from reference (NIH 1998). 
*Disease risk for Type 2 diabetes, hypertension, and cardiovascular disease. 












Disease Risk* (Relative to Normal Weight and 
Waist Circumference) 
Men ≤102 cm 
Women ≤ 88 cm 
> 102 cm 
> 88 cm 
Underweight < 18.5  - - 
Normal† 18.5–24.9  - - 
Overweight 25.0–29.9  Increased High 










≥ 40 III Extremely High Extremely High 
 
Adipose tissue is one of the main types of a connective tissue which mainly 
comprises adipocytes. Besides adipocytes, adipose tissue contains the stromal vascular 
fraction (preadipocytes, fibroblasts, vascular endothelial cells) and a variety of immune 
cells (Frayn, Karpe et al. 2003). Adipose tissue is a complex, essential and highly active 
metabolic and endocrine organ and a main energy store of the body (Kershaw and Flier 
2004). Beside the two main function of white adipose tissue (WAT) which are 
lipogenesis (fatty acid synthesis and storage) and lipolysis (mobilization or hydrolysis of 




(Proença, Sertié et al. 2014). Adipokines play a critical role in many biological 
functions, for example regulation of carbohydrate and lipid metabolism, regulation of 
food intake and insulin sensitivity (Fasshauer and Bluher 2015). Besides adipokines, 
monoamines (epinephrine, norepinephrine (NE), dopamine (DA) and serotonin (5-HT)) 
via dopaminergic and noradrenergic pathways play a key role in regulating 
carbohydrate and lipid metabolism (D’Souza and Abraham 2016). 
Excess adiposity and adipocyte dysfunction result in dysregulation of 
adipokines, which may contribute to impaired glucose (Antuna-Puente, Feve et al. 
2008) and lipid metabolism (Cao 2014, Tang 2016) as well as inflammatory responses 
(Balistreri, Caruso et al. 2010). Previous studies suggest that chronic inflammation in 
adipose tissue may play a significant role in the development of obesity-related 
metabolic dysfunction (Hotamisligil 2006, Lumeng and Saltiel 2011). Adipocyte 
dysfunction is also commonly associated with vascular diseases, like hypertension 
(Zhou and Qin 2012) and atherosclerotic vascular disease (Hajer, van Haeften et al. 
2008, Lee, Wu et al. 2010). 
The detrimental effects of obesity on health are due to the enlargement of 
adipose tissue, particularly visceral adipose tissue. In mammals, there are two main 
types of adipose tissue, the WAT, which stores energy, and brown adipose tissue 
(BAT), which generates body heat. Moreover, researchers recently discovered another 
type of adipose tissue. After thermogenic stimuli brown adipocytes may appear in 
WAT, derived from precursor cells which are different from the classical BAT and are 
closer to the white adipocyte cell lineage. This process is called “browning”. These 
adipocytes are often referred as "inducible, beige, or brite adipocytes" (Giralt and 
Villarroya 2013). The adipose tissue divided into different regional depots with 
variation in biological function, structural organization and cellular size (Bjørndal, Burri 
et al. 2011). The main WATs are subcutaneous adipose tissue and visceral adipose 
tissue. Visceral fat, also known as organ fat or intra-abdominal fat is located between 
internal organs and torso, inside the peritoneal cavity. Visceral fat is composed of 
several adipose depots including mesenteric, epididymal white adipose tissue (omental) 






Figure 1. (A) The main white adipose tissues (WATs) are abdominal subcutaneous adipose 
tissue (SAT, (a)), and visceral adipose tissue (VAT). VAT surrounds the inner organs and can be 
divided in omental (b), mesenteric (c), retroperitoneal ((d): surrounding the kidney), gonadal 
((e): attached to the uterus and ovaries in females and epididymis and testis in men), and 
pericardial (f). The omental depot stars near the stomach and spleen and can expand into the 
ventral abdomen, while the deeper mesenteric depot is attached in a web-form to the intestine. 
The gluteofemoral adipose tissue (g) is the SAT located to the lower-body parts and is measured 
by hip, thigh, and leg circumference. WAT can also be found intramuscularly (h). Brown 
adipose tissue is found above the clavicle ((i): supraclavicular) and in the subscapular region 
(j). Although the mentioned subcutaneous and visceral adipose tissues are found in humans, 
depots (d) and (e) are mostly studied in rodents. (B) The adipose tissue depots that have been 
linked to risk of developing obesity-related diseases are indicated in red. The best-documented 
link to risk is found for the omental and mesenteric VAT. Figure was adopted from reference 
(Frayn, Karpe et al. 2003). 
 
Researchers first started to focus on visceral obesity in the 1980s when they 
realized that the distribution between the fat depots is more important than the total 
adipose tissue mass for the risk of developing obesity-associated diseases. Visceral 
obesity greatly increases the risk of several diseases, such as T2DM (Golay and Ybarra 
2005, Wells 2017), non-alcoholic fatty liver disease (Lopez-Velazquez, Silva-Vidal et 
al. 2014), dyslipidemia (Jung and Choi 2014), cardiovascular disease (Eckel 1997, 
Poirier, Giles et al. 2006), certain types of cancers (Gallagher and LeRoith 2015), and 
depression (Luppino, de Wit et al. 2010). Obesity and its metabolic complications are 




which can prevent or treat obesity and the co-morbidities associated with advanced 
obesity are intensively studied (Ferdinandy, Hausenloy et al. 2014) (Figure 2). 
 
Figure 2. Medical complications of obesity. 
GORD- gastro-oesophageal reflux disease, FSGS- Focal Segmental Glomerulosclerosis. 
Figure was adopted from: Emmanuel J.J., Coppack S.W. (2016) Health Consequences–Obesity 
Associated Comorbidities. In Agrawal S. (eds) Obesity, Bariatric and Metabolic Surgery. 
Springer, Cham). 
 
1.1.2 Therapies for treatment of obesity 
The purpose of treatment of overweight and obesity is to reduce body weight 
and prevention of weight regain and thus to reduce the consequent health risks. Weight 
reduction can be achieved by a combination of the following: lifestyle interventions 




suppressants, metabolism inducers, absorption inhibitors) (Cannon and Kumar 2009). 
All of these interventions are very important in the treatment of obesity but in this thesis 
we only focus on pharmacological therapy. 
Nowadays, beside the pharmacotherapeutic treatment of obesity, cell-based 
therapies are getting more attention. Numerous studies suggest that, therapies using 
adipose-derived stem cells (ADSCs) (Illouz, Sterodimas et al. 2011, Payab, Goodarzi et 
al. 2018) or ADSCs-derived exosomes (Zhao, Shang et al. 2018) seems to be a potential 
treatment strategy to manage obesity and related metabolic disorders in the near future. 
At the beginning of anti-obesity pharmacotherapy investigation, in the 70s, 
centrally-targeted and sympathetic-like agents showed very promising effects on 
decreasing body weight. These drugs activated the sympathetic nervous system 
inducing the release of catecholamines, meanwhile promoted satiety and reduced 
appetite (Motycka, St Onge et al. 2011). However, despite of these encouraging 
findings, numerous serious side effects occurred during the application of anti-obesity 
drugs. Due to the lack of sufficient efficacy and/or due to safety issues several drugs 
have been withdrawn from the market in the last 10 years. In 1973, US Food and Drug 
Administration (FDA) approved the combined pharmacological therapy fenfluramine-
phentermine, and it was pulled out from the market in 1997 following life-threatening 
side effects such as pulmonary hypertension, and heart diseases (Connolly, Crary et al. 
1997). Furthermore, rimonabant, a synthetic CB1 receptor inverse agonist was 
withdrawn in 2009 because patients exhibited increased depression and suicide risks 
(Moreira and Crippa 2009). Sibutramine, a serotonin (5-HT) or 5-hydroxytryptamine-
norepinephrine reuptake inhibitor, was withdrawn from the market in 2010 due to 
increased risk of cardiovascular events (Krentz, Fujioka et al. 2016). 
At present there are only few available anti-obesity drugs on the market 
(Srivastava and Apovian 2018) (Table 2). One of them is lorcaserin, with higher 
selectivity for the 5-HT2C receptors and less side effects than previous 5-HT agonists 
(fenfluramine and dexfenfluramine). In 2013, Fleming et al. showed that chronic 
injections of lorcaserin significantly decreasing food intake and body weight in high-fat 
diet obese-induced rats (Fleming, McClendon et al. 2013). Furthermore, Phase III 




and well tolerated in Type 2 diabetic patients and in non-diabetic patients, respectively 
(Greenway, Shanahan et al. 2016). Another anti-obesity drug in the market is Qnexa, 
which is the combination of phentermine and topiramate. Qnexa significantly decreases 
body weight (Garvey, Ryan et al. 2012) and improves obesity-related metabolic 
dysfunctions such as waist circumference, blood pressure, triglycerides and cholesterol 
levels, however, topiramate has teratogenic potential and increases the heart rate (Shin 
and Gadde 2013). Orlistat is the only anti-obesity drug which is driven by a peripheral 
approach and it has been on the market for more than 10 years. Orlistat reduces dietary 
fat absorption in the small intestines by inhibiting gastrointestinal lipase, however, may 
occur as a side effect the malabsorption of fat-soluble vitamins (Cahill and Lean 1999), 
severe liver injury (Sall, Wang et al. 2014) and kidney injury (Dietrich and Horvath 
2012). 
However, despite all the significant achievements, the current pharmacological 
treatments for obesity are only modestly effective and have several side effects. 
Therefore, further research is needed to develop a novel strategy to enhance the 
effectiveness of obesity treatment and to reduce side effects, including repurposing of 
drugs already in use or development of novel agents. 
 
Table 2 Anti-obesity drugs. 
Table was adopted from reference (Srivastava and Apovian 2018) and (Dietrich and Horvath 
2012). CNS- central nervous system, CV- cardiovascular; EMA- European Medicines Agency, 
FDA- US Food and Drug Administration, GLP-1- Glucagon-like peptide-1 
*If applicable. ‡Never approved by the FDA owing to concerns related to adverse psychiatric 
side effects. 
 
Drug  Mechanism of action Side effects  Comments  
Approved 
Phentermine  • An amphetamine that 




• CV elevation in blood 
pressure, tachycardia  
• CNS: insomnia, restlessness, 
alters sexual behaviour, 
hormonal secretion and mood  
• Approved by the 
FDA in 1959  
• Recommended for 
short-term use (less 




Table 2 (continued) 
Drug Mechanism of action Side effects Comments 
Orlistat  • Pancreatic lipase 
inhibitor 
• malabsorption of fat-soluble 
vitamins, steatorrhoea, fecal 
incontinence, flatulence  
• Rare cases of severe liver 
injury 
• Approved by the 
FDA in 1999  
Lorcaserin  • 5-HT receptor agonist 
that is more specific 
than previous 
compounds on the 
market, for example, 
fenfluramine 
• Headache, dizziness, nausea, 
valvulopathy  
• Possible carcinogenic effects 
in rodents  
• Approved by the 
FDA in June 2012  
• Under evaluation 
by the EMA  
• Post-marketing, 
long-term CV 










• Possible teratogenic effects 
with topiramate  
• Can increase heart rate  
• Approved by the 
FDA in July 2012  
• Post-marketing, 
long-term CV 






• Bupropion: inhibitor 
of dopamine and 
noradrenalin uptake 
• Naltrexone: μ-opioid 
receptor antagonist 
• Nausea, constipation, 
vomiting, dizziness, insomnia, 
dry mouth, and diarrhea 
•Approved by the 
FDA in 2014 
•Approved by the 
EMA in 2015 
Liraglutide 
3.0 mg 
• GLP-1 analogue, 
binding to the same 
receptors as does the 
endogenous hormone 




vomiting, headache, decreased 
appetite, dyspepsia, fatigue, 
dizziness, abdominal pain, and 
increased lipase 
• Approved by the 
FDA in 2014 
Withdrawn 
Fenfluramine  • Increases the release 
of serotonin 
• Serotonin re-uptake 
inhibitor 
• Hallucinations, valvulopathy, 
pulmonary hypertension  
• Approved by the 
FDA in 1973  
• Withdrawn in 1997  
Sibutramine  • Noradrenalin and 
serotonin re-uptake 
inhibitor 
• Increased risk of heart attack 
and stroke in patients with 
high risk of CV disorders  
• Approved by the 
FDA in 1997  
• Withdrawn in 2010  
Rimonabant  • Cannabinoid 1 
receptor antagonist 
• Risk of suicide  • Approved by the 
EMA in 2006‡  




1.1.3 Monoamine oxidase (MAO) inhibitors 
Monoamines (epinephrine, NE, DA and 5-HT) participate in many physiological 
activities of the body. Monoamines are released from the synapse and exert their actions 
by activating dopaminergic, serotonergic and noradrenergic pathways. Monoaminergic 
signaling plays a critical role in regulating cognitive processes, as well as involved in 
the regulation of carbohydrate and lipid metabolism. MAOs are ubiquitous enzymes and 
they are responsible for the oxidative deamination of monoamines and they are found 
bound to the outer membrane of mitochondria in most cell types of the body. MAOs 
contain the covalently bound cofactor FAD, therefore, they are classified as 
flavoproteins. In mammals there are two subtypes of MAO: MAO-A and MAO-B. Both 
enzymes found in neurons and astroglia. Nevertheless, there are differences between 
their tissue distribution outside the central nervous system and the substrate selectivity 
of the two enzymes (Adeghate and Parvez 2004). MAO-B is mostly found in platelets 
and generally metabolizes DA, benzylamine and phenylethylamine. In contrast, MAO-
A is found in the liver, pulmonary vascular endothelium, gastrointestinal tract and 
shows greater affinity for NE, 5-HT, DA and tyramine. 
MAO inhibitors have two main groups: selective and non-selective, within these 
we distinguish reversible and irreversible inhibitors. At present, MAO inhibitors are 
mostly used for psychiatric and neurological disorders (Fiedorowicz and Swartz 2004, 
Finberg and Rabey 2016). MAO-B inhibitors (selegiline, rasagiline) are primarily used 
alone or in combination to treat Alzheimer’s and Parkinson’s diseases (Cai 2014, Dezsi 
and Vecsei 2017). MAO-A inhibitors (clorgyline, moclobemide) generally used as 
antidepressant (Meyer, Ginovart et al. 2006, Corbineau, Breton et al. 2017) and 
antianxiety drugs (Lader 1976). 
However, in recent decades the use of MAO inhibitors by psychiatrists is 
significantly decreased; this decline is in context with the increase in the number of 
available novel antidepressants and with the concern about food- (Berlin and Lecrubier 
1996, Flockhart 2012) and drug interactions (Sjöqvist 1965, Aboukarr and Giudice 
2018). Nevertheless, since researchers showed that MAOs are highly expressed in 




dependent regulation of lipid metabolism in adipocytes (Pizzinat, Marti et al. 1999), 
thus, they may play an important role in obesity and lipid metabolism disorders and it 
may be an useful drug target in metabolic diseases. 
Previous studies have shown that semicarbazide sensitive amine oxidase 
inhibitors administered in combination with certain non-selective and/or irreversible 
MAO inhibitors can reduce body weight and fat deposition in animal models of diet-
induced obesity (Carpene, Iffiu-Soltesz et al. 2007, Carpene, Abello et al. 2008). Mattila 
et al. showed that administration of pargyline (30 mg kg
-1
) increased lipolysis and levels 
of plasma free fatty acid in rats (Mattila and Torsti 1966). Furthermore, diet-induced 
obesity increased MAO activity in the enlarged omental WAT of dogs (Wanecq, Bour 
et al. 2006). Selegiline is a clinically widely used, irreversible and selective inhibitor of 
MAO-B, which is primarily used to treat Parkinson's disease (Jankovic and Poewe 
2012, Zhao, Cai et al. 2013, Chiu, Carlsson et al. 2014, Cereda, Cilia et al. 2017), 
Alzheimer's disease (Riederer, Lachenmayer et al. 2004) and depression (Fiedorowicz 
and Swartz 2004, Pae, Patkar et al. 2014, Thomas, Shin et al. 2015). However, it has 
also been shown to have pleiotropic effects not related to the MAO-B inhibition 
(Tatton, Ju et al. 1994, Tatton, Chalmers-Redman et al. 2002). Békési et al. showed that 
selegiline (5–10 mg kg
-1
) significantly decreased liver fat but not body weight in rats 
fed with a lipid-rich diet (Bekesi, Tulassay et al. 2012) (cholesterol 1%, olive oil 10%). 
Therefore, we hypothesized that MAO inhibitors may have favourable metabolic 
effects in obesity. 
 
1.2 Cardiovascular diseases (CVDs) 
CVDs such as heart failure, hypertensive heart disease, cardiomyopathy, cardiac 
arrhythmia and coronary artery diseases (angina and myocardial infarction) are leading 
causes of morbidity and mortality worldwide (Pagidipati and Gaziano 2013, Roth, 
Johnson et al. 2017). Only in 2015, 17.7 million people died from CVDs in the world. 
Most of these deaths occurred in low-income and middle-income countries (WHO 
2018). Nearly 300 risk factors play a role in the development of CVDs. These include 




consumption, inherited factors, age and psychosocial stress, etc. (Balakumar, Maung-U 
et al. 2016). 
The most common type of CVD is myocardial infarction (MI). Only in 2015, 
about 15.9 million MI occurred, worldwide (Vos, Allen et al. 2016). MI occurs when 
the blood flow reduces or stops for a part of the heart that causes an oxygen and nutrient 
depletion in the heart muscle, which leads to myocardial necrosis (Boateng and Sanborn 
2013). Most myocardial infarction in the world is due to atherosclerosis, when a 
coronary artery becomes occluded following the rupture of an atherosclerotic plaque, 
which leads to the formation of a blood clot. Besides atherosclerosis, many other factors 
may also cause myocardial infarction such as hyperthyroidism, low red blood cell count, 
or low blood pressure. 
 
1.2.1 Therapies of CVDs 
In the management of patients with heart disease, besides pharmacotherapy, 
cardioprotective interventions (Bousselmi, Lebbi et al. 2014, Thuret, Saint Yves et al. 
2014, Aimo, Borrelli et al. 2015) and cell therapies (Reed, Foldes et al. 2013, Goradel, 
Hour et al. 2018) are becoming more and more important. In this thesis we focus on 
pharmacotherapy which is a major treatment modality in CVDs. The purpose of 
pharmacological therapies is to prevent CVDs and to improve patient outcomes. The 
use of current cardiovascular drugs such as antiplatelet drugs, anticoagulants, nitrates, 
beta-blockers, renin-angiotensin inhibitors, and statins depends on the heart condition 
and symptoms (Table 3). However, despite all the achievements in this field, there are 
still certain types of CVDs that do not have appropriate therapies. Furthermore, a major 
problem is that there are no adequate targets for treating several diseases, such as 
ischemic heart disease. Therefore, a further major objective of drug development is 
finding new cardiovascular agents (Stern and Lebowitz 2010, Huffman and Bhatnagar 






Table 3 Classes of drug used in cardiovascular diseases 
ACE- angiotensin-converting-enzyme; ARBS- Angiotensin II Receptor Blockers. Table was 
adopted from: http://www.secondscount.org/treatments/treatments-detail-2/medications- 
cardiovascular-disease#.W7MQhHszbDf. 
Medication type Purpose Possible Side effects, Interactions, and Special 
Instructions 
ACE Inhibitors and 
ARBS 
To lower blood 
pressure and allow 
blood flow more 
easily from the heart 
Dizziness, cough, low blood pressure. Kidneys 
and potassium levels should be monitored with 
blood tests. 
Antiarrythmics To control irregular 
heartbeat 
Depends on the class of drugs. Channel blockers 
can cause headaches, ankle swelling. 
Amiodarone can increase sensitivity to sunlight 
and affect eyesight. 
Antiplatelet 
Medications 
To thin the blood and 
help prevent and 
dissolve clots in 
arteries and stents 
Stomach pain, headache, dizziness, and 
breathing difficulties. Side effects more severe 
in patients with asthma and allergies. Take with 
food. 
Aspirin To prevent and 
dissolve clots in the 
arteries 
Stomach upset, headaches, and drowsiness. An 
allergic reaction could cause breathing 
difficulties. Other severe side effects include 
blood in the stool or coughing blood. Take with 
food to reduce risk of upset stomach. 
Beta-Blockers To lower blood 
pressure and heart 
rate 
Dizziness, fatigue, dry mouth, slow heart rate, 
weight gain, cold hands and feet. May reduce 
side effects if taken with food. 
Thrombolytics To restore blood flow 
during a heart attack 
or stroke and to break 
up blood clots in the 
legs (deep vein 
thrombosis) 
Bleeding, abnormal heart beat, new clotting. 
Anticoagulants To prevent blood 
clots from forming in 
the arteries and heart 
Bleeding, vomiting or coughing blood, blood in 
stool, headaches, and dizziness. Do not take 
with aspirin unless directed by doctor. 
Digoxin To improve your 
heart's ability to 
pump blood and 
helps to slow down 
an irregular heartbeat 
Side effects are more common if too much is 
taken and may include nausea, vomiting, 
diarrhea, stomach pain, loss of appetite, unusual 
tiredness, and slow heartbeat. Take on an empty 
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Table 3 (continued) 
Medication type Purpose Possible Side effects, Interactions, and Special 
Instructions 
Statins To lower your 
cholesterol level, 
reduce the risk of 
heart attacks, strokes 
Muscle pain, liver damage, memory loss, 
nausea, gas, diarrhea, constipation, rash. 
Diuretics  To lower blood 
pressure 
Frequent urination, dehydration, blurred vision, 
fatigue, rash, loss of appetite. Monitor blood 
pressure and kidney function. 
Vasodilators To widen the blood 
vessels to increase 
the flow of blood and 
lower blood pressure 
Headaches, nausea, and dizziness (especially 
older people). Do not drink grapefruit juice. 
May interact negatively with cold medicine. 
 
A number of cardioprotective interventions have been shown in the last decades, 
which reduced ischemic injury in animal models but failed to induce cardioprotection in 
human studies (Bolli, Becker et al. 2004). Then, numerous studies demonstrated that the 
efficacy of cardioprotective therapies is significantly affected by comorbidities such as 
obesity, diabetes or dyslipidaemia (Paulson 1997, Yi, Sun et al. 2011). For example, 
patients with T2DM have increased sensitivity to ischemia-reperfusion (IR) injury and 
that endogenous cardioprotective mechanisms are also inhibited (Ferdinandy, Schulz et 
al. 2007). Moreover, it has been shown that not only chronic diseases but also acute 
changes, such as acute hyperglycemia, can negatively affect cardioprotective 
interventions (Baranyai, Nagy et al. 2015). Furthermore, several publications reported 
that hypercholesterolemia changes cellular signalling and metabolism, thereby 
attenuates pharmacological and non-pharmacological cardioprotective interventions 
(Andreadou, Iliodromitis et al. 2017). In 2016, Ma et al. reported that remote ischemic 
preconditioning-induced cardioprotection was abolished in hypercholesterolemic rats by 
alteration of PI3K-Akt-GSK3b signaling pathway. In another study, Koncsos et al. 
showed that hypercholesterolemia-induced decrease in basal autophagy and increase in 
apoptosis leads to loss of cardioprotection (Giricz, Koncsos et al. 2017). 
Therefore, a growing amount of evidence suggests that increased autophagy 
plays a critical role in cardioprotective interventions (Huang, Yitzhaki et al. 2010, 
Giricz, Mentzer et al. 2012) and that besides MAO inhibition, autophagy could be a 





Autophagy is an intracellular degradation process which eliminates unnecessary 
or dysfunctional organelles and long-lived proteins through lysosomal breakdown for 
recycling intracellular components (Gustafsson and Gottlieb 2008). Accordingly, 
autophagy is primarily considered as a cytoprotective process. However, excessive self-
degradation has detrimental effects. Therefore, autophagic dysfunction is related with 
different human pathologies, such as liver, and heart disease, neurodegeneration, cancer 
and metabolic diseases (Rubinsztein, Codogno et al. 2012). In mammalian cells, three 
main types of autophagy are commonly described: microautophagy, chaperone-
mediated autophagy (CMA) and macroautophagy. 
Microautophagy is a process which involves the direct engulfment of 
cytoplasmic material into the lysosome. The cytoplasmic contents enter the lysosome 
through an invagination or deformation of the lysosomal membrane (Li, Li et al. 2012). 
The second type of autophagy, CMA is a very complex and extremely selective for a 
subset of cytosolic soluble proteins (Kaushik and Cuervo 2008). Macroautophagy, 
(herein referred to as autophagy) eradicate damaged cell organelles or unused proteins. 
Autophagy consists of sequential steps: the initiation phase, which includes formation 
of the autophagosomal membrane also known as a phagophore that is usually derived 
from lipid bilayer contributed by the endoplasmic reticulum or the trans-Golgi. During 
sequestration phase, the phagophore expands and engulf protein aggregates or 
dysfunctional organelles and finally constitute a spherical double-membraned 
autophagosome. This is regulated by the autophagy proteins Atg4, Atg7, LC3, and the 
complex of Atg12-Atg5-Atg16L. In the degradation phase, autophagosome matures via 
fusion with lysosome, this structure is called autophagolysosome. This step initiates the 
degradation of the inner membrane of the autophagosome and cytoplasm-derived 
materials by lysosomal hydrolases. Lysosomal permeases and transporters export amino 
acids and other products of degradation to the cytosol for use by the cell in biosynthetic 
processes or to generate energy (Mizushima 2007, He and Klionsky 2009, Parzych and 
Klionsky 2014). Mitophagy is a specific type of autophagy, which means the selective 




Under normal circumstances autophagy has a low activity in cells but metabolic 
stress such as nutrient starvation or hypoxia can increase the activity of autophagy. 
During metabolic stress degradation of intracellular components promotes cell survival 
by maintaining cellular energy levels. Furthermore, the role of autophagy in the 
development of metabolic disorders (insulin resistance, diabetes mellitus, obesity, 
atherosclerosis) has been studied extensively using different genetic animal models 
(Kim and Lee 2014). Therefore, the use of autophagy-inducing agents could be an 
effective therapy in cardiovascular diseases and metabolic diseases. 
 
Figure 3. Autophagy mechanisms and signaling pathways. (macroautophagy, mitophagy and 
microautophagy). 






1.2.3 Compounds influencing autophagy 
Previous studies reported that several therapeutic agents which are already in 
clinical use, for example hydrophobic statins (Andres, Hernandez et al. 2014), 
sevoflurane (Shiomi, Miyamae et al. 2014), sulfaphenazole (Huang, Liu et al. 2010) and 
certain antibiotics, such as chloramphenicol (CAP) (Prigione and Cortopassi 2007), may 
also induce autophagy in addition to their primary effects (Levine, Packer et al. 2015, 
Schiattarella and Hill 2016) (Table 4). 
Table 4 Compounds that induce autophagy. 
AMPK- AMP-activated Protein Kinase, cAMP- Cyclic adenosine monophosphate, mTORC1- 
mammalian target of rapamycin complex 1, ULK1- Unc-51 like autophagy activating kinase. 
Table was adopted from reference (Levine, Packer et al. 2015). 
Compound Mechanism of autophagy induction 
FDA approved drugs 
Carbamazepine  Lowers inositol and Ins(1,4,5)P3 levels 
Clonidine  Lowers cAMP levels 
Lithium Lowers inositol and Ins(1,4,5)P3 levels 
Metformin  Upregulates AMPK, which phosphorylates ULK1 and beclin 1 
Rapamycin (and rapalogs) Inhibits mTORC1 
Rilmenidine Lowers cAMP levels 
Sodium valproate Lowers inositol and Ins(1,4,5)P3 levels 
Verapamil Inhibits L-type Ca
2+
 channel, lowering intracytosolic Ca
2+
 
Statins  Depletion of geranylgeranyl diphosphate activates AMPK 
Tyrosine kinase inhibitors  Inhibit Akt-mTOR signaling and beclin 1 tyrosine 
phosphorylation, increase beclin 1/Parkin interaction 
Investigational drug 
BH3 mimetics  Disrupt binding between beclin 1 and Bcl-2 family members 
Chloramphenicol Increase in formation of Atg12-Atg5 conjugates, and in beclin-
1 and LC3-II levels 
Nutritional supplements 
Caffeine  Inhibits mTOR signaling 
Omega-3 polyunsaturated 
fatty acids 
Inhibit Akt-mTOR signaling; disrupt beclin 1 and Bcl-2 
binding 
Resveratrol  Activates sirtuin 1 
Spermidine Acetylase inhibitor 
Vitamin D  Calcium signaling, hCAP18/LL37-dependent transcription of 




Since previous studies reported that CAP protects the heart against 
ischemia/reperfusion injury and upregulates autophagy markers (He, Chen et al. 2001, 
Granville, Tashakkor et al. 2004, Sala-Mercado, Wider et al. 2010). It has been shown 
that the induction of autophagy is required for cardioprotective mechanisms but no 
detailed investigation has been performed on which stage of autophagy is necessary for 
cardioprotection. Since autophagy is a multi-step process, it can be inhibited at different 
steps. Previous studies have shown that inhibition of early-stage autophagy can be 
achieved by 3-methyladenine (Li, Liu et al. 2015) and wortmannin which are inhibit the 
class III phosphatidylinositol-3 kinase, or TAT-HA-Atg5K130R, a dominant negative 
mutant fusion protein of a key mediator of autophagy, Atg5 (Pyo, Jang et al. 2005, 
Hamacher-Brady, Brady et al. 2006, Hamacher-Brady, Brady et al. 2007). The late 
phase of autophagy, lysosomal fusion and degradation, can be arrested by elevating 
lysosomal pH, e.g., by the use of an antimalarial drug, chloroquine (CQ, see for review: 
(Kimura, Takabatake et al. 2013)). Although a few studies utilized these substances to 
investigate the mechanism of cardioprotective stimuli, it is still unknown which phase 
of CAP-induced autophagy is necessary for cardioprotection. 
Therefore, here we hypothesized that CAP induces cardioprotection, via 





Therefore, we had the following aims: 
 To investigate the effect of selegiline treatment on metabolic parameters in high-
fat, high-sucrose diet-induced moderate obesity, together with alterations in 
hemodynamic parameters and markers of neuropathy and behavioural patterns. 
 To investigate whether CAP-induced autophagy is necessary for cardioprotection. 
 To assess whether sequestration and/or degradation phases of autophagy are 





This investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH publication No. 85-23, 
revised 1996) and was approved by the animal ethics committee of the San Diego State 
University, San Diego, California and Semmelweis University, Budapest, Hungary. 
Furthermore, conforms to Directive 2010/63/EU and was authorized by the regional 
animal health authority in Hungary (registration numbers: XIV-I-001/450-6/2012). 
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, 
Browne et al. 2010, McGrath and Lilley 2015). 
 
3.1 Study designs 
3.1.1 Study design: diet-induced experimental obesity 
5-7 weeks old male Long-Evans rats (RRID: RGD_2308852) were purchased 
from Charles River Laboratories (Wilmington, MA, USA). We chose Long-Evans rats 
for our study which are commonly used for experiments on diet-induced obesity (Li, 
Zhang et al. 2008, Estridge, Dey et al. 2017). Furthermore, this strain is leaner as 
compared to Sprague-Dawley and Wistar rats, therefore, the effects of mild obesity 
could be studied with higher reliability in this strain. Furthermore, our laboratory has 
already experience with this strain in metabolic studies (Koncsos, Varga et al. 2016). 
Animals were housed in conventional animal house, 4 animals were housed in a 
polyethylene EUROSTANDARD TYPE IV S cages (480 x 375 x 210 mm) containing 
corncob bedding from J. Rettenmaier & Söhne GmbH & Co and housed in a room 
maintained in a 12/12 h light/dark cycle and constant temperature of 21 °C. Animals 
were allowed access to food and water ad libitum. After 1 week of acclimatization, rats 
were randomly divided into two groups: control (CON; n=20) and high-fat, high-
sucrose group (HFS; n=20). The CON group was fed control rat chow, whereas the HFS 






Table 5 Composition and nutritional data of chows. 
Data are expressed as g/100g or otherwise noted. CON- control, HFS- high-fat, high-sucrose. 
 
 CON HFS 
Corn 58 18 
Gluten/corn 25 30 
Sugar 0 15 
Lard 0 20 
Fasermix (straw pellet) 6 6 
Sodium chloride 0.4 0.4 
Zeolite, universal 6.7 6.7 
Mono calcium phosphate (MCP) 1.5 1.5 
Feed lime 1.3 1.3 
Adhesive 0.6 0.6 
Vitamin and trace element 
supplement 
0.5 0.5 
Gross energy (Mj/kg) 15.52 20.31 
 
From week 16, groups of animals were further randomly divided and received 
subcutaneous injections of 0.25 mg kg
-1
 selegiline (CON+S and HFS+S) or vehicle 
(CON, HFS) once daily (n=10 in each group). Previous articles showed that rats treated 
with daily subcutaneous dose of 0.25 mg kg
-1
 selegiline selectively inhibited the B form 
of the enzyme, leaving the activity of the A form practically unchanged. With a higher 
(1 mg kg
-1
) dose the selectivity was nearly lost (Knoll 1978, Heinonen, Anttila et al. 
1994). 
Body weights were measured monthly. Blood was taken, and fasting blood 
glucose levels were measured from the saphenous vein every month (Accu-Check; 
Roche, Basel, Switzerland). At week 24, oral glucose tolerance test (OGTT) was 
performed on conscious overnight fasted rats with per os administration of 1.5 g kg
-1
 
glucose and measurements of plasma glucose levels at 15, 30, 60, and 120 min. Insulin 
tolerance test (ITT) was also performed at week 24 in overnight fasted rats. Insulin (0.5 
IU/kg, Humulin R; Ely Lilly, Utrecht, The Netherlands) was injected intraperitoneally 
(i.p.), and plasma glucose levels were checked at 15, 30, 45, 60, 90, and 120 min. At 




metabolic cage. At week 25 of the diet animals were sacrificed, anesthetized with 
pentobarbital (60 mg kg
-1
, intraperitoneally; Euthasol; Produlab Pharma, 
Raamsdonksveer, The Netherlands). After hemodynamic measurements, epididymal 
and interscapular brown fat tissue, markers of adiposity, were isolated, and their weights 
were measured. Blood and tissue samples were collected and stored at −80 °C (Figure 
4.). To exclude the natural variability between weights, organ weights were normalized 
to tibia length (Tsujita, Muraski et al. 2006, Nemeth, Matyas et al. 2016). 
 
 
Figure 4. Experimental protocol. 
Male Long-Evans rats were fed with control (CON, n=10) diet or with high-fat, high sucrose 
(HFS, n=10) diet for 25 weeks; CON+S (n=10) and HFS+S (n=10) groups were treated with 
0.25 mg kg-1 selegiline (S) from week 16 to 24. Body weights and blood glucose were measured 
monthly. Neuropathy, behavioural tests were measured at weeks 22-23. Oral glucose tolerance 
test (OGTT), insulin tolerance test (ITT), metabolic cage and CT (computed tomography) were 
performed at week 24. Hemodynamic analysis was performed at week 25. Tissue sampling was 





3.1.2 Study design: effect of CAP on autophagy in different cardiac cells 
To identify the most suitable model system, in a pilot study we examined the 
effect of CAP on autophagy in neonatal rat cardiomyocytes (NRCMs), in H9c2 cardiac 
myoblast cells and in isolated hearts. We found that CAP induced autophagy in isolated 
hearts but not in NRCMs or in H9c2 cells (see Figure 14A–C). The efficacy of CAP and 
TAT-HAAtg5K130R was also assessed in a pilot experiment where we observed that 
LC3-II/I ratio was decreased after 15 min of administration of 200 nM TAT-HA-
Atg
5K130R
 in isolated hearts as compared to vehicle controls (Figure 14D). 
Therefore, in the main series of experiments, we used an ex vivo model of acute 
cardiac ischemia/reperfusion injury to assess the effects of autophagy inhibitors (TAT-
HA-Atg5
K130R
 and CQ) on CAP-induced cardioprotection. Since the availability of 
TAT-HA-Atg5
K130R
 was limited due to technical limitations in production and 
purification of the protein in quantities necessary for ex vivo heart perfusion 





3.2 Evaluation of whole body fat 
To assess obesity, computed tomography (CT) measurements were performed 
on NanoSPECT/CT PLUS (Mediso, Budapest, Hungary) at week 24. The semicircular 
CT scanning was acquired with a 55 kV tube voltage, 500 msec exposure time, 1:4 
binning, and 360 projections in 18 min. During the acquisitions, rats were placed in a 
prone position in a dedicated rat bed and were anesthetized with 2% isoflurane in 
oxygen. Temperature of the animals was kept at 37.2 ± 0.3 °C during imaging. In the 
reconstruction, 0.24 mm in-plane resolution and slice thickness were set, and 
Butterworth filter was applied (volume size: 76.8×76.8×190 mm). Images were further 
analysed with VivoQuant (inviCRO, Boston, MA) dedicated image analysis software 
products by placing appropriate volumes of interest on the whole body fat of animals. 
The aim of segmentation was to separate the fat from other tissues. The connected 




and then the isolated points were detected by erode 4 voxel and dilate 4 voxel steps. 
After the measurements, animals recovered from anaesthesia. Adiposity index was 
calculated by the following formula: (CT whole body adipose tissue volume/body 
weight) ×100. Subcutaneous and total visceral fat volumes were evaluated on CT 
images by CTan software (Bruker microCT, Kontich, Belgium). 
 
3.3 Immunohistochemistry 
For immunohistochemistry, deparaffinized sections underwent antigen retrieval 
(pH=6 citrate buffer, at 95 °C for 15 min). After blocking endogenous peroxidase 
activity (Bloxall, Vector Laboratories, Burlingame, CA, USA), the sections were 
blocked in appropriate sera (2.5% goat serum in PBS). The primary antibody 
recognizing the monocyte/macrophage-specific protein Iba-1 (Wako Pure Chemical 
Industries, Chuo-Ku, Osaka, Japan), was incubated with the sections overnight in 
blocking solution at 4°C. After the primary antibody incubation, the sections were 
washed three times in PBS and incubated for an hour with an anti-rabbit IgG peroxidase 
polymer (ImmPress reagents, Vector Laboratories, Burlingame, CA, USA). Secondary 
antibodies were washed 3 times for 10 min and the specific signal was developed with 
diaminobenzidine (ImmPACT DAB EqV Peroxidase (HRP) Substrate, Vector 
Laboratories, Burlingame, CA, USA). The specific staining was visualized and images 
were acquired using Leica DM3000 LED microscope and MC 190 HD camera (Leica 
Microsystems, Wetzlar, Germany). 
After routine formalin-fixed paraffin-embedded specimen processing, 4 µm 
thick tissue sections were prepared and stained with hematoxylin and eosin (H&E), for 
histological evaluation of adipocyte morphology. Adipocyte cross sectional area was 





3.4 Adipocyte cross sectional area 
Adipocyte cross sectional area was measured with the ImageJ-based software, 
Adiposoft (Galarraga, Campion et al. 2012). Images of adipocyte cross sectional area 
were subtracted using ImageJ and then analyzed with Adiposoft without using 
automated method. Cells which were smaller than 25 µm in diameter were excluded. 
Analyzed images were edited using manual method in Adiposoft. 
Cells on the borders of image were excluded, separated sections that clearly 
belonged to one cell were merged together, and cells which were not recognized by 
software were added and analyzed manually. Adipocyte tissue areas in µm² were then 
further used for analysis. 
 
3.5 Total RNA isolation 
Total RNA from white adipose tissue (epididymal) was extracted with a 
precipitation method. Briefly, RNAzol® RT (Sigma, USA) was added to each sample 
and homogenized with TissueLyser (Qiagen, Germany). Homogenates were 
centrifuged, and DNA and protein were precipitated with nuclease-free water. 
Furthermore, 4-bromoanisole (Sigma), phase separation step was incorporated to 
maximize the DNA elimination. Total RNA was precipitated with isopropanol (vWR, 
USA), and pellet was washed twice with ethanol (vWR, USA). Finally, total RNA was 
resuspended in nuclease-free water. RNA concentrations were measured with 
NanoDrop (Thermo Scientific, Waltham, USA). 
 
3.6 cDNA synthesis and qRT-PCR 
Total RNA was used as a template for cDNA synthesis, using Sensifast cDNA 
synthesis kit (Bioline; BLI 65053) according to the manufacturer’s protocol. qRT-PCR 
reactions were performed with a LightCycler® 480 Real-Time PCR System (Roche 
Diagnostics, Germany) in the presence LightCycler® RNA Master SYBR Green I 
(Roche; 03064760001) according to the manufacturers protocol. Forward and reverse 




carboxylase (Acc), adipose triglyceride lipase (Pnpla2), diglyceride acyltransferase 
(Dgat), fatty acid translocase (Cd36), sterol regulatory element-binding protein 1c 
(Srebp-1c), NADH dehydrogenase 1 alpha (Ndufa1), monocyte chemoattractant protein 
1 (Ccl2) and macrophage inflammatory protein 1-alpha (Ccl3), glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) were used for analysis. Hprt was used as reference 
gene. Results were calculated with 2log-ΔΔCp evaluation method. Sequences of 
primers are indicated in Table 6. 
Table 6 Sequences of primers 
Primer Forward Reverse 
Acc TGAGGAGGACCGCATTTATC GCATGGAATGGCAGTAAGGT 
Cd36 CCAGAACCCAGACAACCACT CACAGGCTTTCCTTCTTTGC 
Dgat TGCTCTTTTTCACCCAGCTT TTGAAGGGCTTCATGGAGTT 
Gapdh TACCAGGGCTGCCTTCTCTTG GGATCTCGCTCCTGGAAGATG 
Glut1 CGGGCCAAGAGTGTGCTGAA TGACGATACCCGAGCCGATG 
Glut4 AGAGTGCCTGAAACC CCCTAAGTATTCAAGTTCTG 
Hprt GTCCTGTTGATGTGGCCAGT TGCAAATCAAAAGGGACGCA 
Ccl2 TGATCCCAATGAGTCGGCTG GCTTGGTGACAAATACTACAGCTT 
Ccl3 GCTGCTTCTCCTATGGACGG TCTCTTGGTCAGGAAAATGACACC 
Ndufa1 GGTTGGAGTGTGAGTAACGGT TCCAGGCCCTTGGACACATAG 
Pnpla2 CACCATCCGTTTGTTGGAGTG GCAGATGCTACCTGTCTGCT 
Srebp-1c CGTTAACGTGGGTCTCCTCC AGCATGTCTTCGATGTCGGTC 
 
3.7 Measurement of plasma lipid, insulin and leptin levels 
Low density lipoprotein (Beckman Coulter LDL-Cholesterol, Ref.: OSR6183), 
high density lipoprotein (Beckman Coulter HDL-Cholesterol, Ref.: OSR6187) and 
triglyceride (Beckman Coulter Triglyceride, Ref.: OSR60118) were measured from 
plasma samples according to the manufacturers protocol by Beckman Coulter AU 5800 




Plasma samples and pulverized pancreas samples were used to determine 
pancreatic insulin content. Analysis was performed with insulin (I-125) IRMA Kit 
(Izotop Kft, Budapest, Hungary) according to the manufacturer's instructions. 
Plasma leptin was measured by ELISA (KRC2281, Invitrogen, Camarillo, CA, 
USA) according to manufacturer's instructions. Technical triplicates were used to ensure 
the reliability of single values. 
 
3.8 Measurement of liver lipid content 
Approximately 50 mg of frozen liver tissue was homogenized with Tissuelyser 
LT (Quiagen, Germany) (50 s-1; 2×3 min) in a closed tube with 1.0-mm metal beads 
and 1.0 mL SET buffer (sucrose 250 mM, EDTA 2 mM, and Tris 10 mM). Complete 
cell destruction was done by 2 freeze-thaw cycles and 3 times passing through a 26-
gauge syringe needle and a final freeze-thaw cycle. Total cholesterol (Beckman Coulter 
Cholesterol, Ref.: OSR6116), and triglyceride (Beckman Coulter Triglyceride, Ref.: 
OSR60118) were measured from homogenized liver samples according to the 
manufacturers protocol by Beckman Coulter AU 5800 Clinical Chemistry System. 
Hepatic cholesterol and triglyceride levels were normalized to protein content, 
measured with the bicinchoninic acid (BCA) method (Thermo Fisher Scientific, 
Waltham, USA) as did in previous article (Houben, Oligschlaeger et al. 2017). 
 
3.9 Hemodynamic measurements 
Arterial blood pressure measurements were performed using a 2F microtip 
pressure microcatheter (SPR-838, Millar Instruments, Houston, USA). Rats were 
anesthetized with pentobarbital (60 mg kg-1, intraperitoneally, Produlab Pharma, 
Raamsdonksveer, The Netherlands), tracheotomized, intubated and artificially 
ventilated, while core temperature was maintained at 37 °C. Thereafter the catheter was 
inserted into the right carotid artery and advanced into the ascending aorta. After 




acquisition system (AD Instruments, Colorado Springs, USA), stored, displayed and 
analyzed on a personal computer by the LabChart Software System (AD Instruments) to 
calculate heart rate, systolic and diastolic blood pressure values. 
 
3.10 Behaviour and nociceptive tests 
To test if altered caloric intake and obesity may influence motor activity, 
motility was measured with a 3 channel CONDUCTA system (EXPERIMETRIA Ltd. 
Hungary). Animals were placed to one of the 48×48×40 cm observation boxes for 30 
min. Their movements were detected with infrared sensors. The time spent with four 
mutually exclusive movement types were analyzed: rearing (vertical activity), 
immobility (complete motionlessness), ambulation (horizontal activity) and local 
movements (non-locomotor activity). 
Novel object recognition assay (NOR) was performed to assess the effects of 
selegiline on HFS diet-induced cognitive dysfunctions. This assay is a model for the 
investigation of visual recognition memory in rodents. The task procedure consists of 
three phases: Day 1: habituation to the test box for 3 min; Day 2: familiarization with 
two identical objects, (trial 1, t1); Day 3: test phase: after 24 h intertrial delay one of the 
familiar objects was replaced by a novel object and the exploration time of each object 
was measured for 3 min (trial 2, t2). The animals were observed through a video camera 
system. Recognition memory was characterised by the discrimination index (DI): 
(t2novel-t2fam)/ (t2novel+t2fam) ×100, where t2novel and t2_fam are exploration time 
of novel and familiar object, respectively, in the test phase in seconds. Therefore, higher 
DI indicates better recognition memory. 
To investigate sensory changes in prediabetes and obesity related to potential 
neuropathic complications, we performed two mechano-nociceptive tests. The dynamic 
plantar aesthesiometer (DPA; Ugo Basile Model No. 37450, Comerio, Italy) is a 
modified method of the classic Von Frey assay to assess touch sensitivity. The animals 
were put in mesh bottom plastic boxes. A blunt-end thin metal filament was targeted to 




the maximum of 50 g with 10 g/sec ramp. Each paw was tested three times and the 
touch sensitivity thresholds were determined. Since this touch stimulus is basically non-
painful for the rat under normal conditions, decreased sensitivity threshold is considered 
as mechanical allodynia. The Randall-Selitto test (Ugo Basile Model No. 18476, 
Comerio, Italy) measures the pressure sensitivity of the paws. The cone-shaped pusher 
of the instrument applied a continuously increasing pressure on the hind paw of the 
loosely held, restrained rat and the pressure threshold of the withdrawal reaction was 
registered. Each hind paw was tested in this assay once. Unlike the touch stimulus, this 
pressure represents a mild painful stimulus under healthy conditions, therefore, 
decreased pressure withdrawal threshold shows mechanical hyperalgesia. The Randall-
Selitto test was performed after the DPA measurement to avoid the possible influence of 
the compression on touch sensitivity. 
 
3.11 Isolation and treatment of NRCMs 
Preparation of NRCM culture used in the pilot study was described before in 
details (Gorbe, Giricz et al. 2010). Briefly, neonatal Wistar rats were sacrificed by 
cervical dislocation and hearts were removed and placed into ice-cold phosphate 
buffered saline (PBS) solution. Ventricles were minced and resuspended in 0.25% 
trypsin (Thermo Fisher Scientific, USA) solution. Digested tissue was centrifuged at 
400 ×g, for 15 min at 4 °C. Cell pellet was resuspended in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with L-glutamine, Antibiotic-Antimycotic solution 
and 10% fetal bovine serum (FBS, Thermo Fisher Scientific, USA). Cells were counted 
in a hemocytometer, and seeded into 75 cm
2
 flasks at a density of 4 ×10
6
 cell/flask. 
After 24 h, the growth medium was replaced with differentiation medium containing 
1% FBS. Cardiomyocytes were kept under normoxic conditions (37 °C, in 95% air and 
5% CO2 gas mixture) for three days prior to treatment and cell collection. On the 3rd 
day of culturing, cell medium was supplemented with vehicle (saline, 5% v/v) or 300 
μM CAP for 1 h. Then cell cultures were washed with ice cold PBS and lysed for 5 min 
in 500 μL homogenization buffer (1× Radio-Immunoprecipitation Assay Buffer, RIPA, 
supplemented with a protease and phosphatase inhibitor cocktail). Lysed cells were 




UP200H, Hielscher, USA) for 10 s on ice. The homogenate was centrifuged at 10,000 
×g, 4 °C for 10 min; and the supernatant was collected and stored at −80 °C. Protein 
concentration was assessed by Bicinchoninic Acid Protein Assay Kit (BCA Protein 
Assay kit, Pierce, USA). 
 
3.12 Treatment of H9c2 cells 
H9c2 cells were seeded in T25 flasks (10
6
 cells/flask) in 6 mL DMEM 
supplemented with 10% FBS, Antibiotic-Antimycotic solution, glucose, MEM Non-
Essential Amino Acid Solution and L-glutamine. Then incubated at 37 °C in 5 % CO2. 
After 24 h cells were treated with 300 μM CAP or vehicle (CON). Cells were incubated 
for 1 h, then scraped in 200 μL RIPA lysis buffer and sonicated (Ultrasonic Processor 
UP200H, Hielscher, USA) for 3 ×15 s at 50% power. Homogenates were centrifuged 
for 10 min at 10,000 ×g, 4 °C. Supernatants were aliquoted and stored at −80 °C. 
Protein concentration was assessed with BCA kit. 
 
3.13 Preparation of K130R 
TAT-HA-Atg5
K130R
 protein was purified from BL21(DE3)pLysS E. coli bacteria 
transformed with pTAT-HA-Atg5
K130R
 plasmid as described elsewhere [8]. Briefly, 
crude cellular extract was purified on a Ni-NTA column (Thermo Fisher Scientific, 
USA) followed by desalting on a PD- 10 column (GE Healthcare, United Kingdom) 
into PBS. Purified protein was used immediately after assessing its concentration by the 
BCA method. 
 
3.14 Ex vivo heart perfusion 
Sprague-Dawley rats (250–300 g) were anesthetized with i.p. pentobarbital (30 
mg/kg) and anticoagulated with i.v. heparin (100 U/kg). Hearts were excised and 




Mocanu et al. 2011). From the 15th min, a group of heart received KH containing 300 
μM CAP. To inhibit CAP-induced autophagosome formation a group of hearts were 
perfused with KH containing 300 μM CAP and 200 nM cell-permeable recombinant 
TAT-HA- Atg5K130R (CAP + K130R) for 15 min at the beginning of the protocol, 
then received CAP alone. Another group of hearts received 300 μM CAP and 10 μM 
CQ (CAP + CQ) throughout the protocol to inhibit lysosomal degradation of CAP-
induced autophagosomes. Further groups of hearts were perfused with 10 μM CQ or 
200 nM TAT-HA-Atg5
K130R
 alone (CQ and K130R, respectively). At the 35 minutes of 
the experimental protocol global ischemia was applied. After the 30 min global 
ischemia, reperfusion was restored. At the end of the 120 min reperfusion, hearts were 
harvested for infarct size evaluation (Figure 5). 
 
Figure 5. Experimental protocol. 
CAP- Chloramphenicol, CQ – Chloroquine; CON- Control, K130R- TAT-HA-Atg5K130R, CK- 





3.15 Measurement of infarct size, coronary flow and creatine kinase release 
At the end of perfusion, hearts were sliced into 2 mm-thick slices, and right 
ventricles were removed. Slices were immersed in 1% triphenyltetrazolium- chloride for 
20 min, then in 4% formalin for 24 h and scanned. Weight of slices was measured. 
Necrotic area was evaluated by planimetry (ImageJ). Data is expressed as a percentage 
of left ventricular mass. Coronary flow rate was measured throughout the protocol by 
timed collection of coronary effluent. Creatine kinase (CK) release was measured in the 
coronary effluent collected from 10 min to 20 min after the onset of the reperfusion by a 
colorimetric assay (Stanbio™ CK Liqui-UV™ Test, Stanbio Laboratory, USA). 
 
3.16 Western blotting 
After 35 min aerobic perfusion, left atria or whole hearts were snap frozen. 
Samples were lysed in 500 μL RIPA buffer with Tissuelyser LT (Quiagen, Germany) at 
4 °C. Lysates were centrifuged at 10,000 ×g at 4 °C for 15 min. Supernatants were 
aliquoted and stored at −80 °C. Protein concentration was assessed by BCA kit, then 
samples containing 40 μg protein were prepared in Laemmli-buffer and electrophoresed 
on 4–12% polyacrylamide gels (Thermo Fisher Scientific, USA), then transferred to 
polyvinylidene difluoride membranes. Even loading was assessed with Ponceau 
staining. Membranes were blocked with 5% non-fat milk or 5% bovine serum albumin 
(BSA) in Tris-buffered saline with 0.05% Tween 20 (TBST) for 2 h. Antibodies against 
LC3 A/B, p-Akt, Akt, p-Erk1/2, Erk1/2 (Cell Signaling, USA) were diluted 1:1000 in 
5% milk or 5% BSA in TBST and added to membranes and incubated for overnight at 4 
°C. After washing in TBST for 3× 5 min, secondary antibody conjugated to horseradish 
peroxidase diluted 1:2000 in 5% milk or 5% BSA in TBST was added for 1 h at room 
temperature. Signals were detected by enhanced chemiluminescence kit (Thermo Fisher 





3.17 Data and statistical analysis 
Data and statistical analysis comply with the recommendations on experimental 
design and analysis in pharmacology (Curtis, Bond et al. 2015). Data analysis was 
performed in a blinded fashion. Group sizes were estimated based on previous 
experiments (Koncsos, Varga et al. 2016). Data are expressed as mean ± standard error 
of mean (SEM). Statistical analysis was performed by two-way ANOVA using Fisher’s 
LSD as post hoc test or One-way ANOVA using Fisher's LSD as post-hoc test or 
Student's t-test or non-parametric Kruskal-Wallis test (coronary flow data, 14–20 min 
timepoint) only if F achieved p<0.05 and there was no significant variance in 
homogeneity by Prism 6 (GraphPad, GraphPad Software, USA). For motor activity 
multivariate analysis of variance was performed as statistical evaluation. Differences 





4.1 HFS diet elevated body weight despite a similar caloric intake 
To investigate the effect of chronic HFS diet and selegiline treatment in rats, we 
measured body weight, food and caloric intake. We found that body weight was slightly 
but significantly elevated in HFS and HFS+S groups from week 16 with a 14% increase 
at the end of the study showing moderate obesity (Figure 6A, B). Observations in 
metabolic cages showed that food intake was lower in HFS and HFS+S groups resulting 
in similar caloric intake in all groups (Figure 6C, D). Chronic selegiline had no 
influence on body weight or food intake. In HFS group one animal died due to 
procedural error. 
 
Figure 6. High-fat, high-sucrose diet increased body weight despite the similar caloric intake 
from week 16. 
(A) Body weight changes during the experiment (n=10) (B) Mean body weights at week 25 
(n=10) (C) Daily food intake (n=8) (D) Daily caloric intake (n=8). Data are presented as mean 
± SEM, *p<0.05 vs. CON, † vs. control diet groups. CON- control; CON+S- 




4.2 Selegiline reduced HFS diet-induced adiposity 
To determine the effects of HFS diet and selegiline treatment on obesity, we 
evaluated adiposity and measured weights of epididymal- and brown adipose tissues 
and organ weights. Selegiline treatment significantly decreased HFS diet-induced 
adiposity (Figure 7A, B). Here we found that total visceral and subcutaneous fat 
volumes increased significantly due to HFS diet and that selegiline treatment reduced 
these elevations in total visceral and subcutaneous fat depots (Figure 7C, D). For 
histological evaluation of adipocyte morphology epididymal adipose tissue sections 
were prepared and stained with H&E (Figure 8). 
 
Figure 7. Selegiline reduced high-fat, high-sucrose diet-induced adiposity. 
(A) Adiposity index at week 24; (B) Representative CT scan (coronal plane). Red shows fat 
tissue. Visceral (C) and subcutaneous (D) adipose tissue volume. p <0.05 * vs CON, # vs HFS, 
† vs. control diet groups. Data are mean ± SEM, CON- control (n=8); CON+S- 






Figure 8. Adipocyte morphology. 
Hematoxylin-eosin staining of epididymal adipose tissue. CON- control (n=10); CON+S- 
control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); HFS+S- high-fat, high-
sucrose+selegiline (n=10). 
 
Furthermore, we measured the size of adipocytes in epididymal and inguinal 
white adipose tissues but neither diet nor selegiline had any influence on adipocyte area 
(Table 7). 
 
Table 7 Adipocyte area. 
CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); 
HFS+S- high-fat, high-sucrose+selegiline (n=10). 
Adipocyte area (µm
2
) CON CON+S HFS HFS+S 
Epididymal adipose 
tissue 
3867.6±612.6 4310.1±424.8 4320.5±259.4 3362.7±271.8 





Weight of epididymal adipose tissue but not perirenal or brown adipose tissue 
was elevated by HFS diet compared to the control group. Furthermore, selegiline 
treatment significantly decreased epididymal adipose tissue weight in HFS diet as 
normalized to tibia length (Table 8). 
 
Table 8 Organs weight normalized to tibia length. 
p <0.05 *vs CON, # vs HFS Data are mean ± SEM. CON- control (n=8); CON+S- 
control+selegiline (n=8); HFS- high-fat, high-sucrose (n=8); HFS+S- high-fat, high-
sucrose+selegiline (n=8). 
Organs weight/ Tibia length 
(mg/mm) 
CON CON+S HFS HFS+S 
Brown adipose tissue 23±1.1 21.5±2.9 25.6±3.6 21.7±2.4 
Epididymal adipose tissue 230.9±27 296.9±22.6# 443.3±47.9* 347.7±21.3*,# 
Heart 41.3±1.7 40.4±1.8 42.4±1.7 43.4±1.1 
Kidney 89.9±4.6 77.8±12.2 93.8±6.2 85.1±12.1 
Liver 445.9±26.5 478.3±32.6 505.3±56.2 496.3±23.1 
Pancreas 34.1±3.4 33.9±4.1 35.3±2.4 33.5±3 
 
We found no significant differences in organ weights, plasma leptin and lipid 
levels. We assessed the blood level of thyroid hormone T3 and T4, and we found no 
difference in their levels due to diet or selegiline treatment (Table 9). To assess effect of 
selegiline on lipid metabolism, we measured free fatty acid levels in the blood but we 
found no difference due to diet or selegiline treatment (Table 9). 
To investigate whether selegiline affects liver lipid content in animals on HFS 
diet, we measured hepatic total cholesterol and triglyceride levels. We found that 
hepatic total cholesterol and triglyceride levels were significantly higher in HFS groups 
compared to CON groups. However, selegiline had no effect on hepatic lipid levels in 








Table 9 Plasma parameters and pancreas insulin content. 
*p <0.05 vs control diet groups Data are mean ± SEM. CON- control (n=8); CON+S- control+ 
selegiline (n=10); HFS- high-fat, high-sucrose (n=8); HFS+S- high-fat, high-sucrose+ 
selegiline (n=7); HDL- high-density lipoprotein, LDL- low-density lipoprotein, T4- thyroxine, 
T3- triiodothyronine. 
  CON CON+S HFS HFS+S 
Plasma triglyceride (mmol/L) 1.26±0.23 1.17±0.17 1.04±0.15 1.28±0.28 
HDL cholesterol (mmol/L) 1.03±0.14 0.96±0.11 0.91±0.15 0.91±0.14 
LDL cholesterol (mmol/L) 0.45±0.06 0.39±0.05 0.55±0.08 0.48±0.08 
Plasma leptin (ng/L) 4.72±0.7 5.29±0.5 5.38±0.6 5.81±0.6 
Plasma insulin (µIU/mL) 113.43±19.7 88.7±6.5 101.7±15.6 109.2±28.9 
Pancreas insulin (µIU/mL) 341.1±45.6 567.1±109.9 597.9±123.4 572.5±118.8 
Hepatic total cholesterol 
(mmol/mg protein) 
0.02±0.002 0.02±0.001 0.03±0.005* 0.03±0.002* 
Hepatic triglyceride    
(mmol/mg protein) 
0.1±0.00 0.1±0.00 0.25±0.09* 0.22±0.03* 
Free fatty acid (pmol/mL) 81.7±17.4 64.9±9.9 66.8±14.9 92.8±15.0 
T3 (pg/mL) 253.0±17.3 293.3±38.0 281.3±19.9 300.6±23.0 
T4 (ng/mL) 51.0±3.0 52.4±3.4 47.6±3.2 54.3±3.2 
 
4.3 Selegiline had no effect on HFS diet-impaired glucose homeostasis 
In our study, we aimed to characterize the changes in glucose homeostasis 
induced by chronic HFS diet. OGTT and ITT tests showed that insulin tolerance 
developed due to HFS diet on week 24 (Figure 9A, B, C, D), although fasting blood 
glucose level (Figure 9E), or plasma and pancreas insulin levels (Table 9) were not 
affected by diet or selegiline treatment. These results suggest that chronic HFS diet led 






Figure 9. High-fat, high-sucrose diet impaired glucose homeostasis. 
(A) Oral glucose tolerance test (OGTT) results at week 24 and (B) Fasting blood glucose levels 
during OGTT (C) Insulin tolerance test (ITT) at week 24 (D) Fasting blood glucose levels 
during ITT (E) Fasting blood glucose levels during feeding period. A-D: n=6, E: n=9-10. Data 
are presented as mean ± SEM. *p <0.05 vs. CON, ‡ vs. CON+S, † vs. control diet groups. 
AUC- area under curve; CON- control; CON+S- control+selegiline; HFS- high-fat, high-





4.4 Selegiline interferes with glucose uptake and lipid metabolism via modulating 
expression of Glut1, Srebp-1c and Ndufa1 in HFS diet 
To examine the glucose uptake in visceral white adipose tissue, we measured 
Glut1, Glut4 expression. In our study, HFS diet significantly increased gene expression 
of Glut1 but not of Glut4 (Figure 10). HFS diet induced the expression of Gapdh in 
adipose tissue, but selegiline did not affect the expression of Gapdh. 
 
Figure 10. Gene expression of carbohydrate metabolism markers. 
Data are presented as mean ± SEM. *p <0.05 vs. CON, # vs HFS, † vs. control diet groups. 
CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); 
HFS+S- high-fat, high-sucrose+selegiline (n=10). 
 
Furthermore, we found that HFS diet induced the expression of Dgat in adipose 
tissue, but selegiline treatment had no effect on this parameter. We also found that 
neither diet nor selegiline had any influence on gene expression of Acc, Pnpla2, and 




expression and selegiline treatment reduced Srebp-1c gene expression in white adipose 
tissue in HFS diet. Furthermore, selegiline may have prevented the HFS diet-induced 
elevation in Ndufa1 in white adipose tissue (Figure 11). 
 
 
Figure 11. Gene expression of lipid metabolism markers. 
Data are presented as mean ± SEM. *p <0.05 vs. CON, # vs HFS,  † vs. control diet groups. 
CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); 




4.5 Selegiline reduces HFS diet-induced inflammation in white adipose tissue by 
modulating expression of Ccl3 
To investigate whether selegiline has effect on inflammation in the white 
adipose tissue, we measured gene expression of markers of adipose tissue inflammation. 
We found no difference in expression of Ccl2 (Figure 12), in the number of 
macrophages in the epididymal and inguinal white adipose tissue (Table 10) and in 
monocyte/macrophage-specific protein Iba-1 staining (Figure 13). 
Table 10 Number of macrophages in adipose tissue samples. 
CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); 
HFS+S- high-fat, high-sucrose+selegiline (n=10). 
Number of adipocytes 
(cells/view field) 
CON CON+S HFS HFS+S 
Epididymal 
adipose tissue 
total 2.8±0.9 3.1±1.1 2.3±1.0 3.4±1.3 
activated 1.1±0.3 1.7±0.6 0.8±0.3 1.9±0.8 
Inguinal adipose 
tissue 
total 2.3±0.4 1.3±0.6 2.1±0.8 2.7±0.4 
activated 1.1±0.3 0.6±0.3 1.3±0.4 0.6±0.2 
 
However, HFS diet induced gene expression of Ccl3 which was reduced by 
selegiline treatment (Figure 12). 
 
Figure 12. Selegiline reduces HFS diet-induced adipose tissue inflammation. 
Gene expression of inflammatory markers. Data are presented as mean ± SEM. p <0.05 * vs 
CON, # vs HFS. → ‘crown-like’ structures CON- control (n=10); CON+S- control+selegiline 





Figure 13. Immunohistochemistry of Iba1 in epididymal adipose tissue. 
CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-fat, high-sucrose (n=9); 
HFS+S- high-fat, high-sucrose+selegiline (n=10). 
 
4.6 Selegiline decreased arterial systolic pressure in control diet 
To examine whether HFS diet or selegiline influences hemodynamic parameters, 
we measured heart rate, arterial systolic and diastolic pressures. We found that 
selegiline significantly decreased systolic pressure in rats fed control diet, however this 
effect was abolished upon HFS diet feeding (Table 11). 
Table 11 Hemodynamic parameters. 
*p <0.05 vs CON Data are mean ± SEM. CON- control (n=6); CON+S- control+selegiline 
(n=5); HFS- high-fat, high-sucrose (n=5); HFS+S- high-fat, high-sucrose+selegiline (n=5). 
 
 CON CON+S HFS HFS+S 
Heart rate (bpm) 408±8 387±13 412±14 393±13 
Arterial systolic pressure (mmHg) 174±2 146±11* 175±8 159±8 




4.7 HFS diet and selegiline did not induce behavioural alterations or sensory 
neuropathy 
Since selegiline improves cognitive functions in aged animals (Brandeis, Sapir et 
al. 1991) and since high-fat diet has been shown to induce cognitive decline (Noble, 
Mavanji et al. 2014), we aimed to assess the effect of selegiline on cognition in our 
model. To investigate the movement pattern and recognition memory, we performed 
spontaneous motor activity test and novel object recognition test at the end of our study. 
Neither HFS diet nor selegiline treatment significantly affected the motor activity 
(Table 12). 
 
Table 12 Measurement of spontaneous locomotor activity. 
Data are mean ± SEM CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-
fat, high-sucrose (n=9); HFS+S- high-fat, high-sucrose+selegiline (n=10). 
Time (min) CON CON+S HFS HFS+S 
Ambulation 3.6±0.3 3.9±0.3 3.2±0.2 3.4±0.3 
Local movement 9.3±0.2 8.7±0.3 9.2±0.2 9.4±0.3 
Immobility 14.6±0.6 13.8±0.6 14.5±0.4 14.7±0.4 
Rearing 2.5±0.3 3.5±0.3 3.1±0.3 2.5±0.2 
 
Furthermore, all groups showed a moderate level of recognition memory: rats 
explored the novel object for 60-80% longer than the familiar one. Neither selegiline 
treatment nor HFS diet caused statistically significant alterations in the performance of 
the animals (Table 13). 
 
Table 13. Novel object recognition assay. 
Data are mean ± SEM. t2
novel
- exploration time of novel object; t2
familiar
- exploration time of 
familiar object; CON- control (n=7); CON+S- control+selegiline (n=9); HFS- high-fat, high-
sucrose (n=8); HFS+S- high-fat, high-sucrose+selegiline (n=8). 
 CON CON+S HFS HFS+S 
T2 novel (sec) 16.9±3.5 13.5±2.3 11.0±1.5 12.0±1.2 
T2 familiar (sec) 10.0±2.1 7.8±0.9 6.1±0.8 6.5±0.7 





For detecting the presence of neuropathy and neuropathic pain in HFS diet we 
performed two nociceptive tests. For testing pressure hyperalgesia, we performed 
Randall-Selitto paw pressure test and for testing mechanical allodynia we used DPA. 
Results showed no difference in pain thresholds between groups neither for DPA nor 
Randall-Selitto experiments (Table 14). These results indicate that disturbed glucose 
homeostasis did not cause neuropathy. 
 
Table 14. Assessment of neuropathy. 
Data are mean ± SEM. CON- control (n=10); CON+S- control+selegiline (n=10); HFS- high-
fat, high-sucrose (n=9); HFS+S- high-fat, high-sucrose+selegiline (n=10). 
 CON CON+S HFS HFS+S 
Pressure sensitivity threshold (g) 195±5 207.5±5 201.9±12 207.8±10 
Touch sensitivity threshold (g) 47.4±2 47.8±1 47.9±2 50±0 
 
4.8 CAP induces autophagy in ex vivo perfused hearts but not in NRCMs and 
H9c2 cells 
In a pilot study we aimed to compare the effect of CAP on autophagy in neonatal 
cardiomyocytes, in H9c2 cells and in ex vivo-treated hearts. Therefore, we used the 
most common autophagy marker LC3 to measure changes in autophagy. In isolated rat 
neonatal cardiomyocytes and in H9c2 cells there was no significant difference in LC3-II 
to I ratio between corresponding CON and CAP groups (Figure 14A, B). Since CAP 
failed to induce autophagy in NRCMs and H9c2 cells, in our further experiments we 
used the isolated rat heart model. In the left atrium of hearts perfused with CAP, the 
ratio of LC3-II to LC3-I was significantly increased after 35 min compared to CON 
samples indicating that CAP induced cardiac autophagy (Figure 14C). We also tested 
the effect of CAP and TAT-HA-Atg5
K130R
 on autophagy-related protein LC3 levels in 






Figure 14. The effect of CAP on autophagy-related protein LC3 levels in (A) NRCMs (n=8) 
(B) in H9c2 cells (n=8) and (C) ex vivo heart lysates (n=6) *p < 0.05 vs. CON (D) Pilot study: 
effect of CAP and TAT-HA-Atg5
K130R
 on autophagy-related protein LC3 levels in whole heart 
(n=2). 
Data are presented as means ± SEM. Chloramphenicol - CAP, Control - CON, Microtubule-
associated protein 1A/1B-light chain 3 - LC3, Neonatal rat cardiac myocytes – NRCMs. 
 
The discrepancy might be attributed to the difference in metabolic status of 
cultured cells and the ex vivo perfused hearts. Since insulin, fatty acids and other factors 
are present in cell culture medium due to the use of fetal calf serum, and since these 




autophagy might be differentially modulated by CAP. Furthermore, the presence of cell 
types other than cardiomyocytes (endothelial cells, fibroblasts) in the heart might also 
contribute to the cardioprotective effects of CAP (see for a recent review: (Hausenloy, 




 blocks CAP-induced cardioprotection in isolated hearts 
In order to assess whether the sequestration and/or degradation phases of 
autophagy are necessary for the cardioprotective effect of CAP, we used ex vivo 
Langendorff heart perfusion experiments. CAP treatment significantly reduced infarct 
size and CK release as compared to CON hearts. Pretreatment with TAT-HA-Atg5
K130R
 
abolished the infarct size limiting effect of CAP, while pretreatment with CQ did not 
interfere with CAP-induced cardioprotection (Figure 15A, B). 
 
Figure 15. (A) Inhibition of autophagosome formation by TAT-HA-Atg5
K130R
 abolishes CAP-
induced cardioprotection (B) Inhibition of autophagosome formation (K130R) abolishes the 
CAP induced CK activity reduction in perfused rat hearts. 
n=3–8 *p < 0.05 vs. CON Data are presented as means ±SEM. CAP- Chloramphenicol; CQ- 
Chloroquine; CON- Control; K130R- TAT-HA-Atg5
K130R
; CK- Creatine kinase. 
 
We also measured LC3 expression in isolated heart samples and the western blot 










Figure 16. The effect of CAP on autophagy-related protein LC3 levels in isolated hearts. 
n=3 *p < 0.05 vs. CON Data are presented as means ±SEM. CAP- Chloramphenicol; CQ- 




Since cardioprotection, as assessed by infarct size and autophagy, as assessed by 
LC3-II to LC3-I ratio, was lower in CAP +K130R group than in CAP group, these 
results indicate that CAP-induced cardioprotection requires the process of autophagy 
sequestrationbut not autophagosomal clearance. To characterize cardioprotective 
signaling mechanisms modulated by CAP, we assessed activation of proteins involved 
in the RISK/SAFE pathway. We found that the phosphorylation of Erk1/2 but not of 






Figure 17. Assessment of cardioprotective pathways from ex vivo whole heart lysates. 
(A) Ratio of p-Akt to Akt signals (B) ratio of p-Erk1/2 to Erk1/2. n =5. CAP- Chloramphenicol; 
CON- Control. 
 
Coronary flow was significantly lower at the beginning of reperfusion (4–5 min) 
in CAP, CQ and CAP +CQ groups compared to CON group. Prior to ischemia (14–20 
min) the coronary flow was lower in CQ and CAP +CQ. After the initiation of 
reperfusion (65–79 min) the coronary flow was decreased in K130R and CQ groups. At 
the end of the reperfusion time (169–185 min) the coronary flow was lower in CAP + 
CQ group compared to CON (Table 15). 
 
Table 15. Measurement of coronary flow in ex vivo perfused hearts. 
*p < 0.05, vs. CON n=3–8 data are presented as means ± SEM. CAP- Chloramphenicol; CQ- 





Perfusion time (min) 
4-5 14-20 65-79 169-185 
CON 14±0.6 14±0.9 8.3±0.7 6.7±0.6 
CAP 12±0.5* 10±1.1 9.8±0.7 6.6±0.4 
K130R 14.3±0.9 9.5±2.5 5.7±0.9* 5.7±0.7 
CAP+K130R 14.9±0.6 10.6±0.3 7.8±0.4 5.3±0.2 
CQ 11±0.3* 9.2±0.4* 5±1.1* 5.7±2.2 





5. 1 Selegiline moderates adiposity induced by HFS diet 
5.1.1 Selegiline reduced subcutaneous and visceral fat depots 
In this thesis, we demonstrated that selegiline, an irreversible MAO-B inhibitor, 
significantly decreased adiposity but not body weight in HFS diet by reducing visceral 
and subcutaneous fat depositions. The effect of amine oxidases inhibition has been 
previously investigated in models of metabolic disorders, which presented somewhat 
divergent results. Carpéné et al. demonstrated that combined administration of 
semicarbazide (300 µmol kg
-1
 day), an inhibitor of semicarbazide-sensitive amine 
oxidase, and of another non-selective MAO-B inhibitor, pargyline (10 mg kg
-1
 day) to 
young male obese Zucker rats (Carpene, Iffiu-Soltesz et al. 2007) or non-obese Wistar 
rats (Carpene, Abello et al. 2008) significantly reduced body weight gain and fat 
deposition by reducing energy intake. Furthermore, pargyline alone was shown to 
reduce body weight to a minor extent in obese Zucker rats (Carpene, Iffiu-Soltesz et al. 
2007), and in control rats (Mattila and Torsti 1966) at doses of 10 and 30 mg kg
-1
 day, 
respectively. These findings are partly in contrast with our current findings, since 
although we found that selegiline at human-equivalent therapeutic doses reduced HFS 
diet-induced adiposity, it neither reduced body weight in control rats, nor affected 
caloric- or food intake. These discrepancies might be attributed to the different models 
of metabolic disorders, to the different doses and type of MAO-B inhibitors used, or to 
the combined inhibition of amine oxidases in the previous study. 
Moreover, here we found that selegiline treatment did not cause significant 
weight gain either in control or HFS diet and that selegiline treatment significantly 
decreased HFS diet-induced subcutaneous and visceral adiposity. These findings 
highlight the advantage of selegiline as an antidepressant medication, since first-line 
antidepressants are known to induce weight gain as a side effect (Abosi, Lopes et al. 
2018), whereas, our results show that selegiline is devoid of such effect, moreover, it 




Therefore, MAO-B inhibition by therapeutic doses of selegiline in the present 
study has beneficial effect only in obesity by reducing adiposity. The effect of selegiline 
on adiposity, especially on visceral adiposity, is important, since visceral adiposity is a 
major risk factor for cardiovascular disease and for diabetes (Gonzalez, Moreno-
Villegas et al. 2017). 
 
5.1.2 Hypothesized mechanisms of the adiposity-lowering effect of selegiline 
We also found that selegiline may have affected energy metabolism in the 
adipose tissue. The exact mechanism behind the adiposity-lowering effect of MAO-B 
inhibitors is unclear. Here we found that HFS diet significantly increased gene 
expression of Glut1 but not of Glut4. Furthermore, selegiline treatment slightly, but not 
significantly reduced gene expression of Glut1 in HFS diet. A previous study showed 
that supra-micromolar concentration of selegiline prevented the stimulation of glucose 
uptake induced by serotonin in cardiomyocytes, indicating a role of MAO in this 
process (Fischer, Thomas et al. 1995). This data indicate that selegiline might modulate 
insulin-independent glucose uptake in the adipose tissue. Furthermore, we found that 
HFS diet induced the expression of Dgat and Gapdh in adipose tissue, but selegiline 
treatment had no effect on these parameters. We also found that neither diet nor 
selegiline had any influence on gene expression of Acc, Pnpla2, and Cd36 in white 
adipose tissue. However, we found that HFS diet induced Srebp-1c expression and 
selegiline treatment tended to reduce Srebp-1c gene expression in white adipose tissue 
in HFS diet, suggesting that selegiline might modulate certain aspects of lipid 
metabolism in the adipose tissue. Effects of MAO-B inhibition on metabolism have 
been previously studied. For example, pargyline reduced lipoprotein lipase activity in 
adipose tissue (Mattila and Torsti 1966). Elsewhere, phenelzine, an antidepressant with 
a potent MAO- and SSAO-inhibitory activity, prevented cell triglyceride accumulation 
and adipose conversion, and also reduced expression of several key adipogenic 
transcription factors, such Srebp-1c (Chiche, Le Guillou et al. 2009), which is in line 




We also assessed parameters of metabolism from the circulation. In our study, 
selegiline treatment did not affect plasma leptin, free fatty acid level or lipid levels both 
in control and in HFS animals. These results conform with data reported by Carpéné et 
al. where treatment with pargyline did not alter lipid metabolism in obese rats (Carpene, 
Iffiu-Soltesz et al. 2007, Carpene, Abello et al. 2008), however, elsewhere, an increase 
in lipolytic rate of adipose tissue and elevation of plasma free-fatty acids were reported 
in non-obese rats treated with pargyline, or non-selective MAO inhibitors iproniazid or 
pheniprazine (Mattila and Torsti 1966). 
We also investigated the effect of selegiline on hormonal regulation of 
metabolism. Here we found that selegiline had no effect on the level of T3 or T4 either 
in control or obese rats which is in line with a previous publication where MAO-B 
inhibition did not modify thyroid hormones in lean rats (Cabanillas, Masini-Repiso et 
al. 1994). 
In summary, these results indicate that selegiline may influence glucose and 
lipid metabolism of visceral white adipose tissue via non-hormonal regulation, by 
modulating expression of Glut1, Srebp-1c and Ndufa1. However, measurement of 
further parameters might be necessary to describe the exact mechanism. 
 
5.1.3 Selegiline alleviates WAT inflammation induced by HFS diet 
Browning of white adipose tissue indicates a metabolic activation. We 
hypothesized that selegiline may influence this phenomenon, however, selegiline 
treatment seems not to affect the browning process per se. Adipose tissue inflammation 
is a severe consequence of obesity. MAO-A was recently proposed to play a role 
regulating alternative macrophage activation via the IL4/IL13 signaling (Cathcart and 
Bhattacharjee 2014). Moreover, several studies have shown that macrophages are 
capable of catecholamine synthesis, which play essential role in lipolysis in the adipose 
tissue (Nedergaard, Bengtsson et al. 2011). Nguyen et al. found that macrophages 
secrete catecholamines to induce lipolytic/thermogenic gene expression changes in 
brown and white adipose tissues (Nguyen, Qiu et al. 2011). In contrast with these 




participate in catecholamine synthesis (Fischer, Ruiz et al. 2017). Nevertheless, a 
recently published articles showed that NE is transported into neuron-associated 
macrophages and degraded by the activity of MAO-A (Pirzgalska, Seixas et al. 2017), 
thus proposing MAO inhibition as a tool to promote lipolysis. Although we have 
growing evidence that MAO-A activity may have important role in inflammatory 
macrophages, there is no information on the role of MAO-B in macrophages as well as 
in adipocytes. Here we found no difference in expression of Ccl2 and in the number of 
macrophages in the epididymal and inguinal white adipose tissue, however, HFS diet 
induced gene expression of Ccl3 which was reduced by selegiline treatment. 
Therefore, inflammation of white adipose tissue might be limited by selegiline, 
however, measurement of other parameters e.g. cytokines might be necessary to further 
elaborate on this aspect. 
 
5.1.4 Selegiline had no influence on HFS diet-induced prediabetes 
Previously it has been shown that MAOs can be found in both the exocrine and 
the endocrine parts of the pancreas of different mammalian species (Feldman and 
Chapman 1975, Feldman, Castleberry et al. 1983, Adeghate and Donath 1990). In 1975, 
Aleyassine et al. demonstrated that MAO inhibitors are able to increase as well as 
inhibit insulin release in vitro, in a dose dependent manner (Aleyassine and Gardiner 
1975), however, their effect on carbohydrate metabolism was not assessed by then. 
In this study, insulin resistance developed in rats due the HFS diet, but neither 
plasma nor pancreas insulin levels nor insulin resistance were affected by selegiline 
treatment. These results suggest that chronic HFS diet-induced prediabetes is not 
alleviated by MAO-B inhibition. In contrast to our results, previous articles 
demonstrated that a high dose of pargyline, reduced blood glucose level in obese and 
non-obese rats (Mattila and Torsti 1966, Carpene, Iffiu-Soltesz et al. 2007). Similarly, 
several studies have reported that competitive inhibition of MAO by high doses of 
benzylamine or tyramine might also alleviate glucose tolerance in animal models of 




Although several publications report that although MAO inhibition might have 
beneficial effects on glucose homeostasis in metabolic derangements, therapeutic and 
safe dose of selegiline might not alleviate glucose tolerance or insulin resistance in diet-
induced obesity. 
 
5.1.5 Behavioural alterations or sensory neuropathy was not observed due to 
HFS diet or selegiline 
Neither selegiline treatment nor HFS diet-induced moderate obesity had 
significant effects on motor activity or recognition memory. Although, previous articles 
showed that extreme obesity induce cognitive dysfunction (Wang, Huang et al. 2016, 
Zanini, Arbo et al. 2017) these changes could not be observed in our model of moderate 
obesity. 
The results of mechano-nociceptive tests indicate that HFS diet did not induce 
peripheral prediabetic neuropathy, and that selegiline did not have any effect on the pain 
threshold either in HFS diet or in control diet. However, previous articles showed that 
metabolic syndrome, including prediabetes can induce peripheral prediabetic 
neuropathy before progression to clinical Type 2 diabetes (Novella, Inzucchi et al. 2001, 
Sumner, Sheth et al. 2003). Relatively little is known about the effect of MAO-B 
inhibitors on pain or analgesia. Hozumi et al. investigated the relationship between 
obesity and neuropathic pain, and they found that obesity and moderate overweight can 
negatively affect neuropathic pain intensity and nerve damage, however, they could not 
find the pathophysiological mechanisms behind these findings (Hozumi, Sumitani et al. 
2016). In this thesis, we showed that moderate obesity induced by HFS diet does not 





5.2 The process of autophagosome formation is necessary for the infarct size 
limiting effect of CAP 
5.2.1 CAP induces cardioprotection via autophagy in ex vivo hearts 
Here we demonstrate that CAP significantly increased the LC3-II/I ratio in ex 
vivo hearts which indicates the induction of autophagy. Furthermore, CAP treatment 
reduced infarct size and creatine kinase activity in isolated rat hearts. These results are 
in agreement with those of Granville et al. (Granville, Tashakkor et al. 2004) who 
showed that CAP reduced infarct size in an open chest rabbit model of regional 
ischemia. Moreover, similar results were obtained in a previous study with a more water 
soluble derivative of CAP, chloramphenicol succinate (CAPS), in a swine model of 
myocardial ischemia reperfusion injury by Sala-Mercado et al. (Sala-Mercado, Wider et 
al. 2010). They found that CAPS, administered as a pre-treatment or before reperfusion, 
rendered the porcine heart resistant to ischemia-reperfusion injury, however, they did 
not investigate which stage of autophagy is necessary for cardioprotection. 
Interestingly, in our present ex vivo rat heart experiment, CAPS did not reduce infarct 
size (data not shown). Since CAPS is a prodrug activated by esterases in the blood 
(Ambrose 1984) which are not present in isolated heart perfusion, our data suggests that 
in vivo metabolism of CAPS into CAP plays a significant role in its cardioprotective 
effect. In 2014 Shiomi et al. (Shiomi, Miyamae et al. 2014) demonstrated that in 
isolated guinea pig hearts sevoflurane reduced infarct size after 30 min, but not 45 min 
of cardiac ischemia. In this experiment, CAP pretreatment extended the time of 
ischemia after which sevoflurane preconditioning reduced infarct size. 
These results well demonstrate that CAP or its derivatives are able to induce or 
facilitate cardioprotection and that autophagy play a significant role in these effects. 
 
5.2.2 Inhibition of autophagosome formation abolish the infarct size limiting 
effect of CAP 
We further investigated whether CAP exerts cardioprotection via autophagy. 




induced cardioprotection and which stage of autophagy is essential for the 
cardioprotective effect of pharmacologically induced autophagy. We used TAT-HA-
Atg5
K130R
 to inhibit autophagosome formation and CQ to investigate the role of 
lysosomal degradation. Atg5 is not known to participate in other pathways besides 
autophagy, and therefore TAT-HA-Atg5
K130R
 is the most specific inhibitor available. 
In this thesis, we showed that pretreatment with an inhibitor of autophagosome 
formation (TAT-HA-Atg5
K130R
, a functional null-mutant protein) abolished the infarct 
size limiting effect of CAP, while pretreatment with an inhibitor of autophagosome-
lysosome fusion (CQ, a blocker of autophagosomal clearance) did not interfere with 
CAP-induced cardioprotection. Similarly, Shiomi et al. found that a non-specific 
autophagy inhibitor, 3-methyladenine, abolished the CAP-induced restoration of 
sevoflurane preconditioning after prolonged ischemic insult (Shiomi, Miyamae et al. 
2014). 
These results clearly show that the sequestration phase of autophagy is essential 
for CAP-induced cardioprotection against acute ischemia/reperfusion injury (Figure 18). 
 
Figure 18. Chloramphenicol-induced cardioprotection requires the sequestration phase of 
autophagy, not the degradation phase. 
The role of autophagosomal clearance in cardioprotection has been investigated 
in several models. Guo et al. (Guo, Xu et al. 2015) showed that 1 h after cardiac 
ischemia LC3-II/I ratio was significantly elevated, and that ischemic postconditioning 




might inhibit cardiac autophagy. However, the same study indicated that inhibition of 
autophagosomal clearance by CQ abolished cardioprotection by ischemic 
postconditioning, which suggests that inhibition of cardiac autophagy might be 
controversial in ischemic conditioning. Similarly, Wang et al. investigated the 
mechanisms underlying resveratrol-mediated cardioprotection, and found that chronic 
inhibition of autophagic clearance with bafilomycin A1 abrogated resveratrol-mediated 
cardiac protection in diabetic mice (Wang, Yang et al. 2014). On the contrary, in our 
present study, acute treatment with CQ did not abolish CAP-induced cardioprotection in 
isolated healthy hearts. 
These findings suggest that although in vivo inhibition of autophagic clearance 
interferes with several types of cardioprotective stimuli, autophagic clearance is not 
likely to be necessary for cardioprotection triggered by pharmacologically-induced 






6.1 Selegiline moderates HFS diet-induced adiposity 
This is the first demonstration that selegiline reduces adiposity, modulates 
adipose tissue energy metabolism and alleviates adipose inflammation induced by HFS 
diet. Here we have shown that HFS-induced expression of Srebp-1c, Glut1, and Ccl3 in 
adipose tissue was alleviated by selegiline treatment. However, in our experiment 
selegiline treatment did not affect the increase in body weight, prevent impairment of 
glucose homeostasis, or affect behaviour. Our results demonstrate that selegiline may 
influence glucose and lipid metabolism of white adipose tissue and may also alleviate 
inflammation in white adipose tissue. 
These results suggest that specific inhibition of MAO-B by selegiline may 
mitigate harmful effects of obesity, and reduce the risk of cardiovascular diseases, 
thereby selegiline may serve as an adjuvant to anti-obesity therapy. 
 
6.2 CAP reduces infarct size via induction of autophagy sequestration 
Here we have shown for the first time in the literature that the sequestration, but 
not the clearance phase of autophagy is necessary for the cardioprotective effect of 
CAP. In our study, CAP administration reduced myocardial infarction in ex vivo rat 
hearts. Due to CAP treatment an increase in the LC3-II/I ratio and in the 
phosphorylation of Erk1/2 could be observed in the heart. The CAP-induced 
cardioprotection was abolished with an inhibitor of autophagosome formation. 
Therefore, therapeutic tools developed on the basis of induction of autophagic 







Obesity and cardiovascular diseases are the leading causes of death worldwide. 
However, despite numerous experimental and clinical trials in this field, there is still no 
safe and effective form of pharmacotherapy for these diseases. 
Therefore, our aim was to investigate novel approaches to alleviate cardiac 
effects of metabolic derangements. We assessed the effect of selective MAO-B 
inhibition on energy metabolism in HFS diet-induced moderate obesity model. We also 
aimed to clarify the role of autophagy in CAP-induced cardioprotection and to 
investigate that sequestration and/or degradation phases of autophagy are necessary to 
induce cardioprotection. 
The MAO-B inhibition by selegiline decreased whole body fat, subcutaneous- 
and visceral adiposity induced by HFS diet. Furthermore, selegiline treatment 
modulated HFS diet-induced expression of lipid and carbohydrate metabolism markers, 
such as Srebp-1c, Glut1 and inflammatory marker, such as Ccl3 in adipose tissue. The 
oral glucose tolerance and insulin tolerance tests showed impaired glucose homeostasis 
in HFS diet groups. We found that selegiline decreased systolic pressure in rats fed 
control diet, however, this effect was abolished upon HFS diet feeding. We also 
demonstrated that CAP induces cardioprotection via increasing cardiac autophagy and 
phosphorylation of Erk1/2 in the myocardium. Furthermore, infarct size and CK release 
were significantly decreased due to CAP treatment. The pretreatment with TAT-HA-
Atg5
K130R
 abolished cardioprotection by CAP, while in CAP+ CQ hearts infarct size and 
CK release were reduced similarly to as seen in the CAP-treated group, showing that 
autophagosome formation is necessary for the CAP mediated cardioprotection. 
Our results help us to get a more comprehensive picture of the molecular 
changes in mild obesity and the effect of MAO-B inhibition on these changes. 
Furthermore, based on the roles of phases of autophagy in triggering cardioprotection, it 







Az elhízás és a kardiovaszkuláris megbetegedések világszerte a vezető halálokok 
közé tartoznak. Azonban, a számos kísérletes és klinikai vizsgálat ellenére, jelenleg 
sincs még biztonságos és hatékony kezelés ezeknek a betegségeknek a kezelésére. 
Ezért célunk az volt, hogy új farmakológiás lehetőségeket vizsgáljunk meg a 
metabolikus elváltozások szívhatásainak kiküszöbölésére. Vizsgáltuk a szelektív MAO-
B gátlás hatását az energia metabolizmusra a magas zsír- és cukor tartalmú étrend által 
kiváltott enyhe elhízásos modellben. Továbbá, célul tűztük ki az autofágia szerepének 
tisztázását a klóramfenikol indukálta kardioprotekcióban. Megvizsgáltuk, hogy az 
autofágia megkötési és/vagy degradációs fázisa szükséges a kardioprotektív hatáshoz. 
A szelegilinnel történő MAO-B gátlás csökkentette a testzsírt, valamint a 
szubkután és a zsigeri adipozitást, melyet a magas zsír- és cukor diéta okozott. Továbbá, 
a szelegilin kezelés csökkentette a zsírszövetben a magas zsír-és cukor diéta által 
indukált lipid-és szénhidrát-metabolizmus markerek expresszióját, mint például a 
Srebp-1c, és a Glut1, valamint a Ccl3 gyulladásos markert. Az orális glükóz tolerancia 
és az inzulin tolerancia teszt károsodott glükóz háztartást mutatott a magas zsír-és cukor 
tartalmú táppal etetett csoportokban. A szelegilin csökkentette a szisztolés nyomást a 
normál táppal etetett patkányokban, azonban ez a hatás eltűnt a magas zsír- és cukor 
diéta következtében. Továbbá kimutattuk, hogy a klóramfenikol kardioprotekciót 
indukál az autofágia és az Erk1/2 foszforilációjának fokozása révén a szívizomban. A 
klóramfenikolos kezelés jelentősen csökkentette az infarktusméretet és a kreatin-kináz 
felszabadulást. A TAT-HA-Atg5
K130R
 előkezelés a klóramfenikol indukálta 
kardioprotekciót megszüntette, míg a klóramfenikollal és klorokinnal kezelt szívekben 
az infarktusméret és a kreatin-kináz felszabadulása hasonló mértékben csökkent, mint a 
klóramfenikollal kezelt csoportban. Ez azt mutatja, hogy a klóramfenikol által 
közvetített kardioprotekcióhoz az autofagoszóma képződése szükséges. 
Eredményeink hozzásegítenek egy átfogóbb kép megalkotásához az enyhe 
elhízásban végbemenő molekuláris változásokról, valamint arról, hogy a MAO-B gátlás 
milyen hatással van ezekre a változásokra. Továbbá az autofágia szakaszainak a 
kardioprotekció kiváltásában betöltött szerepének megismerése lehetővé teszi célzottabb 
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